AmplifyBio will be exhibiting at the Society of Toxicology Meeting in San Diego, California: May 27th – May 31st. Like many people, the team at AmplifyBio is looking forward to getting out and meeting with customers and colleagues in person again.
AmplifyBio is a leading preclinical CRO focused on toxicology, safety and pharmacology testing to advance therapeutics for the betterment of human health. Spun out of Battelle in May of 2021, AmplifyBio was created to continue to provide exceptional CRO study services in an agile environment better suited to commercial goals and with expanded analytic capabilities to serve the dynamic needs of drug development. The result for our customers is the peace of mind that comes from direct access to highly experienced study directors, scientists, and program managers, our decades of experience in GLP and non-GLP study design and execution, combined with rapid investment in technology, and infrastructure to provide the critical components of a strong partnership.
“Society of Toxicology is a particularly important show for us this year as it will be a chance for legacy customers who knew us as Battelle to learn more about the exciting investments and expansions we are making while also letting other commercially focused and advanced therapies companies learn about our state of the art facility for the first time,” says Jerry Hacker, EVP and Chief of Commercial for AmplifyBio
The foundation of our preclinical CRO expertise remains in our ability to support customers from study design through end-point delivery, whether for a single study or a complete IND-enabling program. AmplifyBio offers a full complement of small and large animal models, including the immunodeficient, immunocompromised, and genetically modified models that are increasingly required. AmplifyBio accommodates a comprehensive list of dose routes and has in-house clinical and anatomic pathology capabilities. Since its launch, AmplifyBiohas significantly expanded the throughput capacity and capabilities in stereology, fluorescent microscopy, digital pathology, and IHC to meet the critical timelines of commercial customers.
The bulk of our investment as AmplifyBio has come in expanding our bioanalytic assay capabilities. We recognize that the spectrum of data that is possible to gather during therapeutic development is broad and growing rapidly. To keep up with those requirements, we expanded our assay systems, methods, and staff expertise in immunology, virology, and molecular biology to support the immunological and molecular techniques that our customers rely on for meaningful decision-making. Some of those platform investments include a state-of-the-art dPCR lab, spectral flow cytometry, and the expansion of bead arrays and ELISA/Fluorospot for immunological and cytokine assessments.
In addition to expanded expertise and technologies, AmplifyBio is focused on being the most responsive partner in the CRO marketplace. To that end, we have grown our study and quality teams to ensure that studies can move efficiently through execution and quality assurance. Customers have direct access to our experts throughout the study, like an extension of their own lab group.
We invite you to request a meeting at SOT to learn more.